Page 2 of Biocon

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical trials.

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

The biosimilar is approved for the treatment of Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis.

Following the development, the company’s share price rose up to 5.69 per cent to hit an intraday high of Rs…

In LMICs, where healthcare budgets are often stretched and large segments of the population remain underserved, the introduction of biosimilars…

Additionally, Biocon Biologics has entered into a commitment agreement for a new syndicated debt facility, the company announced.